Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $606.20 million. The enterprise value is $499.61 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, after market close.
| Earnings Date | May 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 96.68 million shares outstanding. The number of shares has increased by 2.97% in one year.
| Current Share Class | 96.68M |
| Shares Outstanding | 96.68M |
| Shares Change (YoY) | +2.97% |
| Shares Change (QoQ) | +4.67% |
| Owned by Insiders (%) | 1.01% |
| Owned by Institutions (%) | 59.66% |
| Float | 73.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.89 |
| P/TBV Ratio | 6.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.41, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.41 |
| Quick Ratio | 10.29 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12,881.00 |
Financial Efficiency
Return on equity (ROE) is -52.59% and return on invested capital (ROIC) is -34.90%.
| Return on Equity (ROE) | -52.59% |
| Return on Assets (ROA) | -32.15% |
| Return on Invested Capital (ROIC) | -34.90% |
| Return on Capital Employed (ROCE) | -51.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.84M |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -30,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +113.44% in the last 52 weeks. The beta is 0.41, so TRVI's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +113.44% |
| 50-Day Moving Average | 5.53 |
| 200-Day Moving Average | 3.83 |
| Relative Strength Index (RSI) | 58.12 |
| Average Volume (20 Days) | 1,496,966 |
Short Selling Information
The latest short interest is 5.50 million, so 5.69% of the outstanding shares have been sold short.
| Short Interest | 5.50M |
| Short Previous Month | 4.68M |
| Short % of Shares Out | 5.69% |
| Short % of Float | 7.47% |
| Short Ratio (days to cover) | 1.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.52M |
| Pretax Income | -38.78M |
| Net Income | -47.91M |
| EBITDA | -51.38M |
| EBIT | -51.52M |
| Earnings Per Share (EPS) | -$0.47 |
Full Income StatementBalance Sheet
The company has $107.62 million in cash and $1.03 million in debt, giving a net cash position of $106.59 million or $1.10 per share.
| Cash & Cash Equivalents | 107.62M |
| Total Debt | 1.03M |
| Net Cash | 106.59M |
| Net Cash Per Share | $1.10 |
| Equity (Book Value) | 99.64M |
| Book Value Per Share | 1.06 |
| Working Capital | 98.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$38.26 million and capital expenditures -$35,000, giving a free cash flow of -$38.29 million.
| Operating Cash Flow | -38.26M |
| Capital Expenditures | -35,000 |
| Free Cash Flow | -38.29M |
| FCF Per Share | -$0.40 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |